Patents Assigned to IMBRIA PHARMACEUTICALS, INC.
  • Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
    Patent number: 11969422
    Abstract: The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: April 30, 2024
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Jaikrishna Patel, Paul Chamberlin
  • Methods of treating kidney conditions using modified forms of trimetazidine
    Patent number: 11883396
    Abstract: The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: January 30, 2024
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Paul Chamberlin
  • Compositions and methods for increasing efficiency of cardiac metabolism
    Patent number: 11844840
    Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.
    Type: Grant
    Filed: May 31, 2022
    Date of Patent: December 19, 2023
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin
  • Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
    Patent number: 11793807
    Abstract: The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: October 24, 2023
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Jaikrishna Patel, Paul Chamberlin
  • Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
    Patent number: 11780811
    Abstract: The invention provides methods of chemical synthesis of the pharmacological agent 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate, also called CV-8972. The methods entail formation of a free base form of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethanol, also called CV-8814, as intermediate without producing a salt form of CV-8814.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: October 10, 2023
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Neil Buckley, Dan Belmont, Bryan Hauser, Myoung Goo Kim, Kumar Kannan
  • Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
    Patent number: 11746090
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: September 5, 2023
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
    Patent number: 11730733
    Abstract: The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: August 22, 2023
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Jaikrishna Patel, Paul Chamberlin
  • CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE
    Publication number: 20230093615
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Application
    Filed: November 14, 2022
    Publication date: March 23, 2023
    Applicant: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
    Patent number: 11530184
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: December 20, 2022
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • Compositions and methods for increasing efficiency of cardiac metabolism
    Patent number: 11376330
    Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: July 5, 2022
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin
  • Compositions and methods for increasing efficiency of cardiac metabolism
    Patent number: 10953102
    Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: March 23, 2021
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin
  • Compositions and methods for increasing efficiency of cardiac metabolism
    Patent number: 10918728
    Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 16, 2021
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin
  • Combination therapy
    Patent number: 10786476
    Abstract: The present disclosure provides certain combination therapy technologies that are particularly useful for treating one or more diseases, disorders, or conditions that may be related to abnormal metabolism. In some embodiments, provided technologies provides combinations of TCA cycle acids and ketone bodies. In some embodiments, provided technologies provides combinations of TCA cycle acids and other carboxylic acids.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: September 29, 2020
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin
  • COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH ALTERED TCA CYCLE METABOLISM
    Publication number: 20200140375
    Abstract: Compositions and methods for treating conditions associated with altered TCA cycle metabolism are provided.
    Type: Application
    Filed: July 24, 2018
    Publication date: May 7, 2020
    Applicants: IMBRIA PHARMACEUTICALS, INC., IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin
  • Compositions and methods for increasing efficiency of cardiac metabolism
    Patent number: 10556013
    Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 11, 2020
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin